MacroGenics, Inc.
9704 Medical Center Drive
Rockville
Maryland
20850
United States
Tel: 301-354-3758
Website: https://macrogenics.com/capabilities/
Email: collaborate@macrogenics.com
About MacroGenics, Inc.
MacroGenics is a biopharmaceutical company developing and manufacturing a portfolio of innovative antibody-based products intended to extend and enhance the lives of people with cancer. We achieve this by leveraging the skills, passion, and scientific expertise of our employees and partners. Part of this mission includes providing our expertise in biopharmaceutical development and manufacturing to CDMO clients via our FDA-licensed commercial manufacturing facility. Our GMP suite utilizes single-use technology for maximum speed and flexibility and is outfitted for production of mammalian drug substance at the 500 L or 2000 L scale. In addition to manufacturing, we offer a fully customizable CDMO package with optional development services and analytical testing.
MacroGenics is committed to redefining CDMO relationships through efficient collaboration, client prioritization and transparency. Ensuring your values align with our company culture is as important to us as ensuring your process fits our facility.
If you are interested in learning more about our CDMO capabilities, come check us out in Rockville, Maryland! Reach out to schedule a meeting and tour of our facility to discuss your CDMO needs.
Stock Symbol: MGNX
Stock Exchange: NASDAQ
256 articles about MacroGenics, Inc.
-
MacroGenics To Host 2016 R&D Day
12/9/2016
-
MacroGenics Provides Update On Corporate Progress And Third Quarter 2016 Financial Results
11/3/2016
-
MacroGenics Announces Date Of Third Quarter 2016 Financial Results Conference Call.
10/27/2016
-
MacroGenics Announces Date Of Third Quarter 2016 Financial Results Conference Call
10/27/2016
-
MacroGenics To Present At The Leerink Partners Rare Disease & Immuno-Oncology Roundtable
9/23/2016
-
MacroGenics Announces The Promotion Of Three Executives
9/21/2016
-
Let's Not Stay Together...Takeda and MacroGenics Nix Agreement
9/12/2016
-
MacroGenics To Participate In Two Upcoming Investor Conferences
8/31/2016
-
MacroGenics To Participate In Two Upcoming Investor Conferences
8/4/2016
-
MacroGenics Provides Update On Corporate Progress And Second Quarter 2016 Financial Results
8/4/2016
-
MacroGenics Announces Date Of Second Quarter 2016 Financial Results Conference Call
7/28/2016
-
MacroGenics Announces Closing Of Collaboration And License Agreement With Janssen To Develop MGD015
6/28/2016
-
MacroGenics Wrangles Cancer Deal Worth $755 Million Out of Johnson & Johnson
5/19/2016
-
MacroGenics, Inc.Provides Update On Corporate Progress And First Quarter 2016 Financial Results
5/5/2016
-
MacroGenics, Inc. Provides Update On Corporate Progress And First Quarter 2016 Financial Results
5/5/2016
-
Servier Walks Away from a $450 Million Cancer Deal with MacroGenics, Inc.
10/28/2015
-
MacroGenics, Inc. Highlights Progress At 2015 R&D Day
10/14/2015
-
MacroGenics, Inc. Announces Proposed Public Offering Of Common Stock
7/14/2015
-
ASCO15: MacroGenics, Inc. Presents Updated Data From Phase I Study Of Margetuximab At ASCO Annual Meeting 2015
6/1/2015
-
MacroGenics, Inc. Preclinical Research On MGD006 DART Molecule Published In Science Translational Medicine
5/28/2015